The emergence and progression of amyloid diseases, including Alzheimer’s disease, are linked with aberrant aggregation of proteins, called amyloids. Elimination of toxic amyloids from organs and living animals is prerequisite for establishing an eradicative medicine to treat amyloid diseases. We expect that selective degradation of amyloids promoted by chemical catalysts in living animals will be a basis for neutralization and elimination of amyloids. I will present our recent progress in the catalyst development endeavor toward in-vivo photooxygenation of amyloid β (Aβ) and its effects on the fates of aggregated Aβ [1].

C–H Functionalization as medicine: Catalytic photooxygenation of Aβ in living mice brains

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.